65,437 trials
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity — 25.9; 11.1; 0; 6.2 percentage of participants
Chronic Hepatitis B
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) at Week 24 Using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine…
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.2; 92.2 Percentage of participants — p=<0.001
Stenosis · Restenosis
Primary: Number of Participants With Freedom From AV Access Circuit Localized or Systemic Serious Adverse Events — 106 Participants — p=0.0021
Type II Diabetes Mellitus · Diabetes Complications
Primary: Change in Cardiac Diastolic Function as Measured by E' (cm/s) — -0.02; 0.55 cm/s — p=0.07
Stress Disorders, Post Traumatic
Primary: Feasibility of the Coping Coach Online Intervention — 35; 19; 1; 9 Participants
Benign Prostatic Hyperplasia (BPH)
Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity — 53.3; 14.7; 1.3; 12.0 percentage of participants
Safety · Pharmacokinetics · Healthy Subjects
Primary: Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab. — 36.22; 82.44; 63.86 ug/mL
Influenza
Primary: Number of Seropositive Subjects for H1N1 Haemagglutination Inhibition (HI) Antibodies — 5; 6 Participants
Neisseria Meningitidis · Bacterial Infections · Virus Diseases
Primary: Percentage of Participants With an Anti-Hepatitis B Surface Antigen (HBsAg) Antibody Titer ≥10 mIU/mL — 98.9 Percentage of Participants
Type 2 Diabetes
Primary: Change From Baseline in Total Score for All Question Items in the Diabetes Therapy Related -QOL (DTR-QOL) Questionnaire at the End of Study — 8.72; 6.35 Units on a Scale…
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAEs) — 4; 3; 5; 2 Participants
Lung Cancer, Non-Small Cell
Primary: Number of Patients Reporting Confirmed Non-small-cell Lung Cancer (NSCLC) Recurrence — 37; 24 Participants — p=0.256
Advanced Cancer
Primary: Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD]) — 40 milligrams (mg)